ISOPTInternational Symposium on Ocular Pharmacology and Therapeutics
References in periodicals archive ?
The Phase 1a clinical results, presented at ARVO, Aegean Retina XI and ISOPT, demonstrated that ACU-4429 was safe and tolerable in healthy volunteers aged 55-80; and dose-dependent modulation of the visual cycle was shown in electroretinography (ERG) measurement, an eye test used to detect abnormal function of the retina (the light-detecting portion of the eye).
The data will be presented during the Retina: Dry AMD portion of the ISOPT program on Saturday, December 5, 2009 at 10:20 a.
As we further advance our clinical development program, it is exciting that ACU-4429 clinical data continue to reinforce our preclinical findings and we look forward to discussing these data in greater detail at ISOPT 2009.